Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2012 Publisher: RB Pharmaceuticals Ltd 103 – 105 Bath Road, Slough Berkshire SL1 3UH
SUBUTEX 2 mg sublingual tablets.
| Pharmaceutical Form |
|---|
|
Sublingual tablet. |
Buprenorphine hydrochloride equivalent to buprenorphine base: 2 mg.
| Active Ingredient | Description | |
|---|---|---|
| Buprenorphine |
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
| List of Excipients |
|---|
|
Monohydrated lactose |
7 or 28 tablets in nylon/aluminium/uPVC blister packs.
RB Pharmaceuticals Ltd
103 – 105 Bath Road, Slough
Berkshire
SL1 3UH
Subutex 2 mg, sublingual tablets: PL 36699/0002
February 1998 (UK)
| Drug | Countries | |
|---|---|---|
| SUBUTEX | Austria, Australia, Germany, Finland, France, Croatia, Ireland, Israel, Lithuania, Malta, Singapore, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
